Alcon Inc (ALC) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation

Third-quarter 2024 sales of $2.4 billion, up 6% on a reported and constant currency1 (cc) basis Third-quarter 2024 diluted EPS of $0.53, up 29...

Alcon Debuts Groundbreaking PRECISION7, a One-Week Replacement Contact Lens to Start and End Every Week Fresh

PRECISION7, a new one-week replacement lens, provides 16 hours of outstanding comfort and precise vision, even on day 71 Features world’s first...

Algoma Central Corporation Reports Financial Results for the 2024 Third Quarter

Increased demand across certain sectors and expanded capacity drives a stronger quarter, signaling a promising close to the year Algoma Central...

Alcon Singapore Elevates Associate Experience with Inspiring Engagement Programs

Alcon Singapore has been recognized as one of the Best Employers in Singapore for three years (2021, 2023 and 2024), securing second place in...

Alcon Innovations on Display at AAO 2024 Demonstrate Efficiency and Performance

Attendees can experience a first look at Voyager DSLT, Alcon’s new first-line laser therapy for glaucoma patients Alcon introduces new handheld...

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses

Record Q2 2024 sales of $2.5 billion, up 3%, or 6% constant currency1 (cc) Q2 2024 diluted EPS of $0.45, up 32%, or 47% cc; core diluted EPS2 of...

Algoma Central Corporation Reports Financial Results for the 2024 Second Quarter

Changing environments across key industrial sectors contributes to challenging quarter but outlook remains positive Algoma Central Corporation...

Alcon’s Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance

Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies...

Form 144 - Report of proposed sale of securities